- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00573820
Far Infrared Radiation Treatment for Prostate Cancer
August 14, 2009 updated by: GAAD Medical Research Institute Inc.
Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Prostate Cancer
A study to determine the use of far infrared radiation for the treatment of prostate cancer.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Our initial assessment indicates that electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to cure a number of diseases, including prostate cancer.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4V 1L5
- The Centre for Incurable Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Persons with Prostate, Bladder or Testicular Cancer.
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1
|
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary end point is to determine the therapeutic effects of far infrared radiation on Prostate Cancer.
Time Frame: 2 years and 6 months
|
2 years and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of cancer (Bladder and Testis).
Time Frame: 2 years and 6 months
|
2 years and 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
February 1, 2008
Study Completion (Anticipated)
December 1, 2008
Study Registration Dates
First Submitted
December 12, 2007
First Submitted That Met QC Criteria
December 12, 2007
First Posted (Estimate)
December 14, 2007
Study Record Updates
Last Update Posted (Estimate)
August 17, 2009
Last Update Submitted That Met QC Criteria
August 14, 2009
Last Verified
August 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GAAD-PC-CTP1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
Clinical Trials on Far Infrared Radiation
-
GAAD Medical Research Institute Inc.UnknownAmyotrophic Lateral SclerosisCanada
-
GAAD Medical Research Institute Inc.UnknownMultiple SclerosisCanada
-
GAAD Medical Research Institute Inc.Unknown
-
GAAD Medical Research Institute Inc.UnknownParkinson's DiseaseCanada
-
GAAD Medical Research Institute Inc.UnknownHuntington DiseaseCanada
-
National Taiwan University HospitalChung Shan Medical UniversityCompleted
-
GAAD Medical Research Institute Inc.Unknown
-
GAAD Medical Research Institute Inc.Unknown
-
GAAD Medical Research Institute Inc.Unknown
-
GAAD Medical Research Institute Inc.UnknownMuscular DystrophiesCanada